{"id":"rosuvastatin-cresnon","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Myalgia (muscle pain)"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"5-10","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"2-4","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rosuvastatin is a statin that competitively inhibits HMG-CoA reductase, which catalyzes the conversion of HMG-CoA to mevalonate in the cholesterol biosynthetic pathway. This inhibition decreases hepatic cholesterol production, leading to upregulation of LDL receptors on hepatocytes and increased clearance of LDL cholesterol from the bloodstream. The net result is a significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:03.383Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary prevention of cardiovascular disease in at-risk patients"},{"name":"Secondary prevention of cardiovascular events in patients with established coronary artery disease"}]},"trialDetails":[{"nctId":"NCT02280590","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2014-09","conditions":"Hyperlipidemia","enrollment":223}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rosuvastatin(Cresnon®)","genericName":"Rosuvastatin(Cresnon®)","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rosuvastatin, marketed as Cresnon, is a small molecule inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase. It is used to treat hyperlipidemia, a condition studied in clinical trials, including a comparison of its efficacy and safety with Crestor.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}